Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial-dose intravenous methylprednisolone trial in generalized myasthenia gravis
jRCTs061240006Recruiting
- Sponsor
- Japan Society for the Promotion of Science
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of methylprednisolone in myasthenia gravis (MG) (2 arms), sponsored by Japan Society for the Promotion of Science. Primary endpoint: Number of patients with increase in MG-ADL score of 2 or more from initiation of IV methylprednisolone therapy. Started May 2024; status: recruiting.
02
Drugs
methylprednisolone
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCTs061240006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061240006.